Pfizer CFO Amit Agarwal leaves: what it means for Pfizer stock

Published on 10/14/2026 at 02:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

For Pfizer stock this means June revenue of INR 653.17 crore, up 8.31 percent year over year. Net profit reached INR 204.47 crore in June 2026.

CFO transition and operating figures

Amit Agarwal left Pfizer Limited as executive director and CFO on October 8, 2026.
June 2026 revenue reached INR 653.17 crore, while net profit was INR 204.47 crore.
Pfizer Limited's P/E ratio was 25.20 as of October 13, 2026.

Pfizer, INE182A01018, Illustration mit AI erstellt.

Pfizer Limited (ISIN INE182A01018) entered a leadership transition after Executive Director and Chief Financial Officer Amit Agarwal left the company on October 8, 2026. StockFin reported the departure as the latest corporate development for the India-listed pharmaceutical company.

Three dated company developments

On July 28, 2026, Pfizer approved results for the quarter ended June 2026, with revenue of INR 653.17 crore and net profit of INR 204.47 crore. Equitymaster reported that revenue rose 8.31 percent year over year and net profit increased 6.63 percent.

On September 7, 2026, Pfizer discontinued the marketing, distribution and sale of Minipress XL after Pfizer Inc. ended manufacturing, with a USD 13.90 million lump-sum payment due to Pfizer Limited. On October 8, 2026, Agarwal's departure shifted attention to financial leadership and governance continuity, according to StockFin.

What does the CFO exit change?

The operating figures give the transition a measurable backdrop. June 2026 operating profit was INR 292.40 crore and earnings per share were INR 44.69, while operating margin stood at 37.90 percent, according to Tickertape.

Pfizer's dated calendar also includes the September 30, 2026, half-year reporting period and the October 8, 2026, CFO transition. The immediate investor question is therefore operational continuity rather than a change in the company's product portfolio.

Valuation and market position

Pfizer Limited had a market capitalization of INR 174.20 billion as of October 13, 2026, while its P/E ratio was 25.20 and its dividend yield was 1.80 percent. Equitymaster placed the 52-week range at INR 3,732.00 to INR 5,561.60 on October 13, 2026.

The company is listed on the NSE under the PFIZER symbol and operates in the pharmaceuticals industry. The combination of 8.31 percent year-over-year June revenue growth and the October 8 leadership change leaves execution and reporting continuity as the clearest near-term measures for the stock.

Market context: Market report BSE Sensex.